Prepare for an investment interest in companies like Celldex that has yet to be seen previously.
I talk about this subject with many people I meet, the subject of what is happening in imuno-oncology, and where it may be going. Most have no idea, even many of those that invest in the markets. This Documentary will likely increase the general awareness, and increase the already growing interest in this growing medical revolution. This film will be released March 30th.
Buy more Celldex
Well Long, this really closes the loop on the story of Rintega, and make it much easier to explain to the FDA.
This is impeccable timing for Celldex.
Questions: Other than needing to report continued progress from ReAct at ASCO, do you see other hurdles Celldex must clear before they ask for FDA approval? And how is the FDA likely to view the P3 trial currently underway? Can they give approval based on ReAct and keep the P3 in tact? Or might they delay approval due to the ongoing P3 and the potential of disturbing that trial?
Thanks in advance.
Enough already. This man murdered a bunch of people. Premeditated murder. Mass murder.
What the president said about the American deserter from the lawn of the WH, proves this president will lie about ANYTHING. Anything at all. This President is not to be trusted.
What he said today, what he says tomorrow, and what he has said in the past, is not to be trusted. EVER.
Compared to Obama, Nixon was an amateur lier. And if you disagree, maybe we should start listing his lies on a regular basis.
And you micro, try saying a little more than calling people racist.
She said, "development stage biotechs that have P3 assets that have yet to be partnered, are driving a lot of value for shareholders." Rintega & Glemba?
Continued consolidation and innovation are reasons to stay in biotech, according to Barbara Ryan.
Even you leftist out there are going to cringe when you hear the details of what they have been up to.
This game of pay to play is not going away, this time.
Longvrts, love the post, and cant agree more. I know you do not often speak of SP, but in your opinion, what are your thoughts on what is holding back the current SP?
You have got to be kidding. This man is watching his house burn, and all he can think of is the leaking faucet.
Is anyone else getting the feeling that BHO is pleased with how things are going in the Middle East, with Islamic extremist challenging for full control through out? Reasonable people who voted for him have got to be second guessing that little move. This man is intent on a full power structure change throughout the world. A change that puts America's or Liberty's enemies on par with Liberty loving countries. And yes, I really think that is what he is doing. God help us all. It's going to get worse for millions of people.
Starting to feel like 1936 all over again.
Those same people would likely show if a representative of Iran was speaking. You know they would.
Rule, There is a high probability that Celldex will see approval of Rintega this year, and we will never hear from you again, so, "sell crazy someplace else, we're all stocked up here."
Did the Secretary of State sign form "OF-109", upon her departing her position as a federal employee? And if she did not sign the departure document, Why?
Big trouble, either way.
Going out on a limb here, she (H Clinton) will not announce her candidacy for President of the US, ever.
It would be stupid to let Roche have any of the future profits of Varli, and if you made them pay now they would make you pay later. Now they can pay later when their patients want the combination of Roche/Celldex.
I like what M is doing. Continued full ownership.
KB, While I understand and agree with your statement on many levels, this company has so much going on simultaneously, anyone of which could take Celldex to 100 plus per share on momentum, and eventually on revenue, and profits.
At the moment results from Varli begin to come in, and if those results are positive, SP will move very swiftly north, but by that time, we will already have Rindo on the market, and supporting the growth story of Celldex.
Buy more Celldex.
Especially those targeting orphan drugs. Indicated that stock picking will be needed going forward in this market, then used biotech as the lead example of such stock picking.